A Prospective, Randomized, Double-Masked Study
The purpose of this study is to evaluate the effect of Rhopressa or placebo (artificial tears) eye drops on intraocular pressure (IOP) in adult patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT) post-selective laser trabeculoplasty (SLT).
The primary purpose of this study is to utilize the FSL3 to help prolong the length of time people with diabetes maintain adherence to GLP-1 and GIP/GLP-1 antagonists. Subjects with type 2 diabetes who are newly beginning glucagon-like peptide 1 (GLP-1) and dual gastric inhibitory polypeptide/glucagon-like peptide 1 (GIP/GLP-1) agonist therapy will be assigned to use either the FSL3 or their existing Standard of Care (SOC) device to manage their type 2 diabetes. Effectiveness will be characterized by assessing the length of time subjects in each group remain on a GLP-1 or GLP-1/GIP combination drug.
The purpose of this study is to find out about the safety and effectiveness of monthly study treatment with abelacimab (hereafter referred to as the study drug) in subjects with atrial fibrillation/flutter (AF) who are not treated with oral anticoagulants because they have been deemed by their responsible physicians or by their own decision to be unsuitable for currently available oral blood thinners.
We are doing this study to learn more about how effective, safe and tolerable an experimental drug called balcinrenone is when used in combination with dapagliflozin for treating patients with heart failure and impaired kidney function and also to better understand the studied disease and associated health problems. Combining balcinrenone with Dapagliflozin is experimental, which means it is not approved by any health authority such as the United States Food and Drug Administration (FDA). Dapagliflozin is an approved drug to treat patients with heart failure, chronic kidney disease and type 2 diabetes mellitus.
The purpose of this research is to find out how well using Continuous Glucose Monitoring (CGM) works to improve glucose control compared to routine care (RC) in people with type 2 diabetes not taking insulin. Routine care for a person with type 2 diabetes is typically to check blood glucose by fingerstick at certain times rather than using a CGM. Comparing CGM and routine care is experimental.
The purpose of this clinical research trial is to look at the effectiveness, safety, and tolerance of combining the investigational trial drug called BI 690517 with empagliflozin (empa) in participants diagnosed with heart failure (HF). Empagliflozin is approved by the FDA for the treatment of heart failure.
In this trial, the investigational new treatment option BI 690517 is compared with a treatment with empa and placebo. You have a 50% chance (much like flipping a coin) of getting BI 690517 with empa, or empa and placebo. Please be aware that you may receive placebo that looks like the trial drug (BI 690517) but does not contain any medicine.
The recently completed dal-GenE study, a clinical trial of over 6,000 patients, evaluated the effects of dalcetrapib in patients with recent ACS and the AA genetic variant. The results of this large study demonstrated that treatment with dalcetrapib did not change the risk of having another cardiovascular event in the majority of patients with recent ACS. However, an analysis was performed which indicated that the COVID-19 pandemic may have impacted the accuracy of this data. When the results collected before the start of the COVID-19 pandemic were evaluated, certain analyses showed that taking dalcetrapib corresponded to a reduction in chance of experiencing a myocardial infarction (heart attack) when compared to those taking placebo (dummy drug). The goal of the present study is to evaluate the effect of dalcetrapib only in patients with the AA genetic variant to confirm these findings of cardiovascular benefit.
The purpose of this study is to evaluate if Armour Thyroid is safe and effective in the treatment of hypothyroidism. This study will compare the effect of Armour Thyroid on hypothyroidism and its safety with synthetic drug T4 (Levothyroxine).
The number of FDA-approved and commercially available options for the treatment of hypothyroidism are limited. Currently, synthetic T4 is the common thyroid replacement therapy. Prior to the mid-1970s, desiccated thyroid, such as Armour Thyroid, was the most commonly prescribed form of thyroid hormone replacement. Some of the patients treated with synthetic T4 continue to have persistent symptoms of hypothyroidism or inadequate improvement of their hypothyroid symptoms. The use of desiccated thyroid (Armour Thyroid) may be beneficial to patients with hypothyroidism.
The study drug ZT-01 is designed to inhibit somatostatin, a hormone that inhibits the glucagon response to hypoglycemia. Thus, ZT-01 may be able to restore glucagon production to prevent hypoglycemia, which could improve both health and quality of life in people with T1DM.
The purpose of this study is:
We understand that enrolling in a clinical trial can raise many questions. How long will the trial last? Are there costs involved? What happens if the treatment doesn’t work for me? Our comprehensive FAQ section is here to address these concerns and more, empowering you with the knowledge you need to make an informed decision. Our goal is to provide answers with empathy and honesty, ensuring you feel supported at every stage of your trial participation. For further details or specific concerns, Read More FAQs to explore all the insights available.
Headquarters
3550 University Blvd South, Suite #101
Jacksonville, FL 32216
Tel: (904) 854-1354
Fax: (904) 854-1355
